Rob
If you look at the Genzyme deal in Mipomersen in 2008, Mipomersen was still in concurrent Phase 1 and 2 trials. Two of the longer Phase 1 trial didn't complete till 2010.
That offer was based on Phase 2a data and for $175m cash, $150m in stock and upto $1.5b milestones payment.
ATL 1103 phase 2a will be proceeding. We can potentially see a similar deal in year if the trial can start ASAP.
ATL 1103 market value on Actomegaly alone could be on par with Mipomersen. The sight disorder market value could also have a high added value in the tune of billion a year.
So your reasoning is totally flaw.
Jimo
Ann: Appendix 4C - quarterly , page-11
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.015(13.0%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $612.7K | 4.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56662 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 600000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |